CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capricor Therapeutics is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who is impatient and wants a clear entry now. The stock has strong analyst support and a major approval catalyst ahead, but the current setup is mixed: price is below the prior close, post-market selling was sharp, technicals are neutral-to-weak, and recent news added litigation and regulatory overhang. I would not buy aggressively at this moment. The better call is to hold and wait for confirmation of stability after the current event-driven volatility.
CAPR is trading at 29.34 after closing well below the previous close of 33.94, with additional post-market weakness of 13.55%. The MACD histogram is negative at -0.232 and still contracting, which points to weakening momentum. RSI_6 at 53.04 is neutral, so the stock is not oversold enough to signal an obvious rebound. Moving averages are converging, suggesting indecision rather than a strong uptrend. Key levels show pivot at 33.426 with support at 31.505 and 30.317; the current price is already below the pivot and approaching lower support, which is not an ideal entry for an impatient buyer.
["Roth Capital, B. Riley, Alliance Global, and Piper Sandler all maintain Buy/Overweight views and raised price targets recently.", "FDA acceptance of the updated BLA and the new PDUFA date of August 22, 2026 remain major approval catalysts.", "Analysts cite first-in-class potential for deramiocel and possible broad Duchenne muscular dystrophy labeling.", "The company ended 2025 with $318M cash, which supports operations through 2027.", "Options positioning is bullish, with low put-call ratios indicating positive trading sentiment."]
["Capricor filed a lawsuit against NS Pharma, and the market reacted with a 13% after-hours drop.", "Recent FDA leadership-related headlines have created added uncertainty for cell and gene therapy approvals.", "Revenue in 2025/Q4 fell to 0, showing no current commercial revenue base.", "Net loss remained large at $30.17M, and EPS was -0.62.", "The stock is trading below the prior close with negative post-market momentum and no AI Stock Picker or SwingMax signal today."]
In 2025/Q4, Capricor reported revenue of 0, down 100.00% year over year, so there was no quarterly sales growth. Net income was -30,170,914, which is still a sizable loss, though the year-over-year comparison improved. EPS was -0.62, also improved versus last year but still negative. Gross margin fell to 0 because revenue was absent. For a long-term beginner investor, the latest quarter does not yet show operating strength, even though cash resources are solid.
Recent analyst trend is strongly positive: Roth Capital raised its target to $43 and kept Buy; B. Riley raised to $63 and kept Buy; Alliance Global raised to $51 and kept Buy; Piper Sandler raised to $58 and kept Overweight. The Wall Street pro view is that approval odds are improving and the stock has significant upside into the PDUFA date. The con view is that the business still has no current revenue, remains loss-making, and is exposed to event-driven binary risk. Overall analyst sentiment is bullish, but it is based on future regulatory success rather than current fundamentals.
